JP4593270B2 - カンプトテシンの２０位のエステル - Google Patents

カンプトテシンの２０位のエステル Download PDF

Info

Publication number
JP4593270B2
JP4593270B2 JP2004509687A JP2004509687A JP4593270B2 JP 4593270 B2 JP4593270 B2 JP 4593270B2 JP 2004509687 A JP2004509687 A JP 2004509687A JP 2004509687 A JP2004509687 A JP 2004509687A JP 4593270 B2 JP4593270 B2 JP 4593270B2
Authority
JP
Japan
Prior art keywords
alkyl
branched
linear
group
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004509687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529935A5 (https=
JP2005529935A (ja
Inventor
マウロ・マルツィ
ドメニコ・アッロアッティ
クラウディオ・ピサーノ
マリア・オルネッラ・ティンティ
ロレダナ・ヴェシ
フランコ・ツニーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale per lo Studio e la Cura die Tumori
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Istituto Nazionale per lo Studio e la Cura die Tumori
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale per lo Studio e la Cura die Tumori, Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Istituto Nazionale per lo Studio e la Cura die Tumori
Publication of JP2005529935A publication Critical patent/JP2005529935A/ja
Publication of JP2005529935A5 publication Critical patent/JP2005529935A5/ja
Application granted granted Critical
Publication of JP4593270B2 publication Critical patent/JP4593270B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
JP2004509687A 2002-05-31 2003-05-28 カンプトテシンの２０位のエステル Expired - Fee Related JP4593270B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002RM000306A ITRM20020306A1 (it) 2002-05-31 2002-05-31 Esteri in posizione 20 di camptotecine.
PCT/IT2003/000329 WO2003101996A2 (en) 2002-05-31 2003-05-28 Esters in position 20 of camptothecins

Publications (3)

Publication Number Publication Date
JP2005529935A JP2005529935A (ja) 2005-10-06
JP2005529935A5 JP2005529935A5 (https=) 2006-07-13
JP4593270B2 true JP4593270B2 (ja) 2010-12-08

Family

ID=11456339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004509687A Expired - Fee Related JP4593270B2 (ja) 2002-05-31 2003-05-28 カンプトテシンの２０位のエステル

Country Status (21)

Country Link
US (2) US7452900B2 (https=)
EP (2) EP2112154B1 (https=)
JP (1) JP4593270B2 (https=)
KR (1) KR101000963B1 (https=)
CN (1) CN100376583C (https=)
AR (1) AR040140A1 (https=)
AT (1) ATE439362T1 (https=)
AU (1) AU2003241161C1 (https=)
CA (1) CA2487252C (https=)
CY (2) CY1109581T1 (https=)
DE (1) DE60328777D1 (https=)
DK (2) DK1509529T3 (https=)
ES (2) ES2432379T3 (https=)
IT (1) ITRM20020306A1 (https=)
MX (1) MXPA04011681A (https=)
PE (1) PE20040533A1 (https=)
PL (1) PL374009A1 (https=)
PT (2) PT2112154E (https=)
SI (2) SI2112154T1 (https=)
TW (1) TWI331151B (https=)
WO (1) WO2003101996A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
NZ550430A (en) 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
ATE540698T1 (de) 2005-07-14 2012-01-15 Wellstat Biologics Corp Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen
CN103864811A (zh) * 2012-12-13 2014-06-18 天津科技大学 一种新颖的10-羟基喜树碱20位衍生物制备方法及其在抗肿瘤药物中的应用
US9962452B2 (en) * 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
WO2016065139A1 (en) 2014-10-24 2016-04-28 Fl Therapeutics Llc 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
CN106279286B (zh) * 2016-08-12 2018-11-30 华中科技大学 一种喜树碱膦酸酯类化合物、其制备方法及应用
CN110577551A (zh) * 2018-06-08 2019-12-17 遵义医学院 喜树碱-甘氨酸-5,6-二溴去甲斑蝥素结合物及其应用
MX2022000474A (es) 2019-07-11 2022-03-11 Sun Pharma Advanced Res Co Ltd Derivados de camptotecina con un resto disulfuro y un resto piperazina.
CN116514829A (zh) * 2020-08-21 2023-08-01 诺茗(北京)生物医药有限公司 一种水溶性抗肿瘤前药及其药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JP3186166B2 (ja) * 1992-02-10 2001-07-11 ロンザ リミテッド サリチロイル−カルニチンおよびその製造方法
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
JP3751025B2 (ja) 1995-12-15 2006-03-01 ザ デクスター コーポレイション 研摩性不織繊維ウェブ材料及びその製造方法
ES2235499T3 (es) 1998-07-30 2005-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena.
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
ATE216998T1 (de) * 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
DE19916945C1 (de) 1999-04-15 2000-10-05 Clariant Gmbh Aromatische Aldehydharze und ihre Verwendung als Emulsionsspalter
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6288072B1 (en) 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates

Also Published As

Publication number Publication date
PE20040533A1 (es) 2004-08-26
EP1509529A2 (en) 2005-03-02
DE60328777D1 (en) 2009-09-24
TW200403246A (en) 2004-03-01
US20050256148A1 (en) 2005-11-17
ITRM20020306A1 (it) 2003-12-01
WO2003101996A8 (en) 2004-04-29
ES2432379T3 (es) 2013-12-03
CN1656101A (zh) 2005-08-17
DK2112154T3 (da) 2013-10-21
DK1509529T3 (da) 2009-12-14
CY1114692T1 (el) 2016-10-05
CA2487252A1 (en) 2003-12-11
US7498340B2 (en) 2009-03-03
US7452900B2 (en) 2008-11-18
CY1109581T1 (el) 2014-08-13
KR20050036910A (ko) 2005-04-20
AU2003241161C1 (en) 2010-03-04
AU2003241161A1 (en) 2003-12-19
US20070213353A1 (en) 2007-09-13
ES2331569T3 (es) 2010-01-08
ITRM20020306A0 (it) 2002-05-31
SI2112154T1 (sl) 2013-12-31
EP2112154B1 (en) 2013-07-24
KR101000963B1 (ko) 2010-12-13
ATE439362T1 (de) 2009-08-15
TWI331151B (en) 2010-10-01
WO2003101996A2 (en) 2003-12-11
CN100376583C (zh) 2008-03-26
JP2005529935A (ja) 2005-10-06
PL374009A1 (en) 2005-09-19
CA2487252C (en) 2010-08-10
PT1509529E (pt) 2009-11-13
EP2112154A1 (en) 2009-10-28
EP1509529B1 (en) 2009-08-12
SI1509529T1 (sl) 2009-12-31
HK1079206A1 (en) 2006-03-31
PT2112154E (pt) 2013-10-02
AU2003241161B2 (en) 2009-10-22
MXPA04011681A (es) 2005-03-31
WO2003101996A3 (en) 2004-01-29
AR040140A1 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
US7498340B2 (en) Esters in position 20 of camptothecins
JP4610743B2 (ja) 抗腫瘍活性を有するカンプトテシン誘導体
EP3917926B1 (en) Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof
US6268375B1 (en) 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
KR100762556B1 (ko) 토포이소머라제 Ⅰ 억제작용이 있는 캄프토테신 β-알라닌에스테르
EP1511752B1 (en) Camptothecins with a modified lactone ring
WO2012007619A1 (es) Proceso de obtención de derivados solubles en agua de 20(s)camptotecina como agentes antitumorales
EP0964865B1 (en) Pharmaceutically active tricyclic amines
EP1603919B1 (en) 7-imino derivatives of camptothecin having antitumor activity
CN100484940C (zh) 一类水溶性喜树碱衍生物及其制备方法和应用
HK1079206B (en) Esters in position 20 of camptothecins
US20040266812A1 (en) (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione
FR2814166A1 (fr) Derives 5-phenoxyindole et leurs applications therapeutiques
HK1089160B (en) 7-imino derivatives of camptothecin having antitumor activity
HK1031222B (en) Camptothecin derivatives having antitumor activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100506

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100817

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100915

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130924

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees